



Weekly U.S. Influenza Surveillance Report

Updated July 19, 2024

FLUVIEW



A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Key Updates for Week 28, ending July 13, 2024

Seasonal influenza activity remains low nationally.

Viruses

Clinical Lab

0.8% (Trend →)
positive for influenza
this week

[\(/flu/weekly/index.htm#ClinicalLaboratories\)](/flu/weekly/index.htm#ClinicalLaboratories)

Public Health Lab

Influenza A(H1N1)pdm09,
A(H3N2), and B viruses were all
co-circulating this week.
[\(/flu/weekly/index.htm#PublicHealthLaboratories\)](/flu/weekly/index.htm#PublicHealthLaboratories)

Virus Characterization

Genetic and antigenic
characterization and antiviral
susceptibility are summarized in
this report.
[\(/flu/weekly/index.htm#VirusCharacterization\)](/flu/weekly/index.htm#VirusCharacterization)

Illness

Outpatient Respiratory Illness

1.4% (Trend →)
of visits to a health care provider this week were for
respiratory illness
(below baseline).
[\(/flu/weekly/index.htm#ILINet\)](/flu/weekly/index.htm#ILINet)

Outpatient Respiratory Illness: Map

This week no jurisdictions experienced moderate,
high, or very high activity.
[\(/flu/weekly/index.htm#ORIAM\)](/flu/weekly/index.htm#ORIAM)

FluSurv-NET

0.1 per 100,000
weekly hospitalization rate.

[\(/flu/weekly/index.htm#FluSurvNet\)](/flu/weekly/index.htm#FluSurvNet)

NCHS Mortality

0.1% (Trend →)
of deaths attributed to influenza this week.

[\(/flu/weekly/index.htm#NCHSMortality\)](/flu/weekly/index.htm#NCHSMortality)

Pediatric Deaths

2
influenza-associated deaths were reported; 1 occurred during 2022-2023 season and 1 occurred during 2023-2024 season.

[\(/flu/weekly/index.htm#PedMortality\)](/flu/weekly/index.htm#PedMortality)

All data are preliminary and may change as more reports are received.

Directional arrows indicate changes between the current week and the previous week. [Additional information \(/flu/weekly/index.htm#Trends\)](/flu/weekly/index.htm#Trends) on the arrows can be found at the bottom of this page.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the [surveillance methods \(/flu/weekly/overview.htm\)](/flu/weekly/overview.htm) page.

Additional information on the current and previous influenza seasons for each surveillance component are available on [FluView Interactive \(/flu/weekly/fluviewinteractive.htm\)](/flu/weekly/fluviewinteractive.htm).

Key Points

- Seasonal influenza activity remains low nationally.
- CDC estimates that there have been at least 35 million illnesses, 400,000 hospitalizations, and 25,000 deaths from flu so far this season.
- There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for higher risk patients.³
- Seasonal flu viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information (<https://www.cdc.gov/respiratory-viruses/index.html>) about COVID-19, flu, and RSV activity on a weekly basis.

U.S. Virologic Surveillance

[\(/https://www.cdc.gov/flu/weekly/overview.htm#LabSurveillance\)](https://www.cdc.gov/flu/weekly/overview.htm#LabSurveillance)

Nationally, the percentage of respiratory specimens testing positive for influenza in clinical laboratories remained stable (change of ≤0.5 percentage points) compared to the previous week. Nationally, influenza A(H1N1)pdm09, A(H3N2), and B/Victoria viruses are all co-circulating. However, the distribution of circulating viruses varies by region. For

regional and state level data and age group distribution, please visit [FluView Interactive](https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html) (<https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>).

Clinical Laboratories


The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.

	Week 28	Data Cumulative since October 1, 2023 (Week 40)
No. of specimens tested	29,863	3,578,813
No. of positive specimens (%)	236 (0.8%)	349,690 (9.8%)
<i>Positive specimens by type</i>		
Influenza A	206 (87.3%)	241,481 (69.1%)
Influenza B	30 (12.7%)	108,198 (30.9%)

Season: 2023-24

Surveillance Area: National

Influenza Positive Tests Reported to CDC by Clinical Laboratories, National Summary, 2023-24 Season, week ending Jul 13, 2024



View Additional Graphs and Data (<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>) | Download Chart Data | Download PowerPoint Presentation

Public Health Laboratories


The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype/lineage.

	Week 28	Data Cumulative since October 1, 2023 (Week 40)
No. of specimens tested	1,010	119,075
No. of positive specimens	117	38,404
<i>Positive specimens by type/subtype</i>		
Influenza A	113 (96.6%)	29,306 (76.3%)
Subtyping Performed	95 (84.1%)	24,757 (84.5%)

(H1N1)pdm09	34 (35.8%)	16,417 (66.3%)
H3N2	61 (64.2%)	8,340 (33.7%)
H3N2v	0 (0.0%)	0 (0.0%)
Subtyping not performed	18 (15.9%)	4,549 (15.5%)
Influenza B	4 (3.4%)	9,098 (23.7%)
Lineage testing performed	4 (100.0%)	7,914 (87.0%)
Yamagata lineage	0 (0.0%)	0 (0.0%)
Victoria lineage	4 (100.0%)	7,914 (100.0%)
Lineage not performed	0 (0.0%)	1,184 (13.0%)

Season: 2023-24 Surveillance Area: National

**Influenza Positive Tests Reported to CDC by Public Health Laboratories,
National Summary, 2023-24 Season, week ending Jul 13, 2024**



Check All A (H3) A (H1N1)pdm09 A (Subtyping not Performed) B (Lineage Unspecified) B (Victoria Lineage)

View Additional Graphs and Data (<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>) | Download Chart Data | Download PowerPoint Presentation

Additional virologic surveillance information for current and past seasons:

Surveillance Methods (</flu/weekly/overview.htm#LabSurveillance>) | FluView Interactive: National, Regional, and State Data (<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>) or Age Data (https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html)

Novel Influenza A Virus:

Five human infections with influenza A(H5) virus were reported by the Colorado Department of Health and Environment.

Five individuals in Colorado, each aged >18 years, tested positive for influenza A(H5) virus. All five had performed disposal and culling operations prior to symptom onset at the same commercial poultry farm where highly pathogenic avian influenza (HPAI) A(H5N1) virus clade 2.3.4.4b, genotype B3.13 had been detected in poultry. All five individuals reported mild symptoms; none were hospitalized; all were offered oseltamivir for treatment; and all are recovering from their illnesses.

All five individuals reported their symptoms to the Colorado Department of Public Health and Environment during daily active monitoring on the farm conducted by public health staff. Specimens were collected from the individuals. Specimens were initially tested at the Colorado State Public Health Laboratory using the Centers for Disease Control and Prevention (CDC) influenza A(H5) assay before being sent to CDC for further testing. The specimens were received and tested at CDC. Specimens from all five individuals were positive for influenza A and A(H5) virus using diagnostic rRT-PCR at CDC. Additional analysis including genetic sequencing is underway.

In response to these detections, additional case investigation and surveillance activities are ongoing by public health officials, including additional specimen collection at this farm from symptomatic individuals. Further symptom screening will continue.

A total of ten people have tested positive for A(H5) virus in the United States since 2022. The first case occurred in April 2022 in Colorado in an individual who had performed poultry culling; the next four occurred in April-June 2024 in individuals who worked with dairy cows in Texas (one case) and Michigan (two cases); followed by these five cases associated with poultry disposal and culling operations in Colorado in July 2024.

Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at <https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html> (<https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html>).

Information about avian influenza is available at <https://www.cdc.gov/flu/avianflu/index.htm> (<https://www.cdc.gov/flu/avianflu/index.htm>).

The latest case reports on avian influenza outbreaks in wild birds, commercial poultry; backyard or hobbyist flocks; and mammals in the United States are available from the USDA at <https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal-disease-information/avian/avian-influenza/2022-hpai> [↗](https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal-disease-information/avian/avian-influenza/2022-hpai) (<https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal-disease-information/avian/avian-influenza/2022-hpai>).

Additional information regarding human infections with novel influenza A viruses:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#NovelASurveillance>) | FluView Interactive (http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html)

Influenza Virus Characterization

[\(/flu/weekly/overview.htm#VirusCharacterization\)](/flu/weekly/overview.htm#VirusCharacterization)

CDC performs [genetic](https://www.cdc.gov/flu/about/professionals/genetic-characterization.htm) and [antigenic](https://www.cdc.gov/flu/about/professionals/antigenic.htm) characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

CDC has genetically characterized 5,077 influenza viruses collected since October 1, 2023.

Virus Subtype or Lineage	Genetic Characterization				
	Total No. of Subtype/Lineage Tested	HA Clade	Number (% of subtype/lineage tested)	HA Subclade	Number (% of subtype/lineage tested)
A/H1	1,872				
		6B.1A.5a	1,872 (100%)	2a	443 (23.7%)
				2a.1	1,429 (76.3%)
A/H3	1,755				
		3C.2a1b.2a	1,755 (100%)	2a.1b	1 (0.1%)
				2a.3a	1 (0.1%)
				2a.3a.1	1,752 (99.8%)
				2b	1 (0.1%)
B/Victoria	1,450				
		V1A	1,450 (100%)	3a.2	1,450 (100%)
B/Yamagata	0				
		Y3	0	Y3	0 (0%)

CDC antigenically characterizes (<https://www.cdc.gov/flu/about/professionals/antigenic.htm>) influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, H3N2, B/Victoria, and B/Yamagata viruses) or neutralization-based [HINT](https://pubmed.ncbi.nlm.nih.gov/30804469/) [\(https://pubmed.ncbi.nlm.nih.gov/30804469/\)](https://pubmed.ncbi.nlm.nih.gov/30804469/) (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2023-2024 Northern Hemisphere recommended cell or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than or equal to 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

Influenza A Viruses

- **A (H1N1)pdm09:** 494 A(H1N1)pdm09 viruses were antigenically characterized by HI, and 493 (99.8%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/67/2022-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines.
- **A (H3N2):** 555 A(H3N2) viruses were antigenically characterized by HI or HINT, and 535 (96.4%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer in HI or reacting at titers that were less than or equal to 8-fold of the homologous virus in HINT) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines.

Influenza B Viruses

- **B/Victoria:** 400 influenza B/Victoria-lineage virus were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines.
- **B/Yamagata:** No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

Assessment of Virus Susceptibility to Antiviral Medications

CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at [U.S. Influenza Surveillance: Purpose and \(https://www.cdc.gov/flu/weekly/overview.htm\) Methods | CDC \(https://www.cdc.gov/flu/weekly/overview.htm\).](https://www.cdc.gov/flu/weekly/overview.htm)

Viruses collected in the U.S. since October 1, 2023, were tested for antiviral susceptibility as follows:

Antiviral Medication			Total Viruses	A/H1	A/H3	B/Victoria
Neuraminidase Inhibitors	Oseltamivir	Viruses Tested	4,990	1,847	1,724	1,419
		Reduced Inhibition	1 (0.02%)	1 (0.1%)	0 (0.00%)	0 (0.00%)
		Highly Reduced Inhibition	5 (0.1%)	5 (0.3%)	0 (0.00%)	0 (0.00%)
	Peramivir	Viruses Tested	4,990	1,847	1,724	1419
		Reduced Inhibition	3 (0.1%)	0 (0.00%)	0 (0.00%)	3 (0.2%)
		Highly Reduced Inhibition	6 (0.1%)	5 (0.3%)	0 (0.00%)	1 (0.1%)
	Zanamivir	Viruses Tested	4,990	1,847	1,724	1,419
		Reduced Inhibition	1 (0.02%)	0 (0.00%)	0 (0.00%)	1 (0.1%)
		Highly Reduced Inhibition	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
PA Cap-Dependent Endonuclease Inhibitor	Baloxavir	Viruses Tested	4,915	1,807	1,703	1,405
		Decreased Susceptibility	1 (0.02%)	0 (0.00%)	1 (0.1%)	0 (0.00%)

Four A(H1N1)pdm09 viruses had NA-H275Y amino acid substitution and one A(H1N1)pdm09 virus had NA-H275H/Y, conferring highly reduced inhibition by oseltamivir and peramivir. One (H1N1)pdm09 virus had NA-I223V and NA-S247N amino acid substitutions and showed reduced inhibition by oseltamivir. Two B viruses had NA-A245G amino acid substitution and showed reduced inhibition by peramivir. One B virus had NA-D197N amino acid substitution and

showed reduced inhibition by zanamivir and peramivir. One B virus had NA-H273Y amino acid substitution and showed highly reduced inhibition by zanamivir and peramivir. One A(H3N2) virus had PA-I38T amino acid substitution and showed reduced susceptibility to baloxavir.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented.

Outpatient Respiratory Illness Surveillance (<https://www.cdc.gov/flu/weekly/overview.htm#ILINet>)


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza and will therefore capture respiratory illness visits due to infection with pathogens that can present with similar symptoms, including influenza viruses, SARS-CoV-2, and RSV. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a more complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is providing integrated information about COVID-19, influenza, and RSV activity on a [website \(https://www.cdc.gov/respiratory-viruses/index.html\)](https://www.cdc.gov/respiratory-viruses/index.html) that is updated weekly. Information about other respiratory virus activity can be found on [CDC's National Respiratory and Enteric Virus Surveillance System \(NREVSS\) website \(https://www.cdc.gov/surveillance/nrevss/index.html\)](https://www.cdc.gov/surveillance/nrevss/index.html).

Outpatient Respiratory Illness Visits

Nationally, the percentage of visits for respiratory illness that were reported through ILINet remained stable (change of ≤ 0.1 percentage points) compared to the previous week and is below the national baseline. All 10 regions are below their region-specific baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

Season: 2023-24 and 5 previous seasons ▾

**Percentage of Outpatient Visits for Respiratory Illness Reported by
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet),
Weekly National Summary, 2023-24 Season and Selected Previous Seasons**



- 2023-24 National Baseline
- 2023-24 Season
- 2022-23 Season
- 2021-22 Season
- 2020-21 Season
- 2019-20 Season
- 2018-19 Season

View National and Regional Level Graphs and Data (<https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>) | Download Chart Data | Download PowerPoint Presentation


Outpatient Respiratory Illness Visits by Age Group

About 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

The percentage of visits for respiratory illness reported in ILINet decreased in the 0-4 years age group and remained stable for all other age groups in Week 28 compared to Week 27.

Season: 2023-24

Percent of Outpatient Visits for Respiratory Illness by Age Group
 Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
 Weekly National Summary, 2023-24 Influenza Season through the Week Ending July 13, 2024



View FluView Interactive (https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html) | Download Chart Data | Download PowerPoint Presentation

Outpatient Respiratory Illness Activity Map

Data collected in ILINet are used to produce a measure of ILI activity* ([/flu/weekly/overview.htm#ILINet](#)) by state/jurisdiction and Core Based Statistical Areas (CBSA).


	Number of Jurisdictions		Number of CBSAs	
	Week 28 (Week ending	Week 27 (Week ending	Week 28 (Week ending	Week 27 (Week ending

Activity Level	Jul. 13, 2024)	Jul. 6, 2024)	Jul. 13, 2024)	Jul. 6, 2024)
Very High	0	0	0	0
High	0	0	1	1
Moderate	0	0	1	0
Low	1	0	3	3
Minimal	54	54	664	677
Insufficient Data	0	1	260	248


A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Outpatient Respiratory Illness Activity Map Determined by Data Reported to ILINet

This system monitors visits for respiratory illness that includes fever plus a cough or sore throat, also referred to as ILI, not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.



2023-24 Influenza Season Week 28 ending Jul 13, 2024



Season: 2023-24 ▲

Download Image

Download Data

(<https://www.cdc.gov/flu/weekly/fluereport.xml>)View Full Screen (<http://gis.cdc.gov/grasp/fluview/main.html>)

*Data collected in ILINet may disproportionately represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

Additional information about medically attended visits for ILI for current and past seasons:

[Surveillance Methods \(/flu/weekly/overview.htm#ILINet\)](#) | [FluView Interactive: National, Regional, and State Data \(http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html\)](#) or [ILI Activity Map \(https://gis.cdc.gov/grasp/fluview/main.html\)](#)

Hospitalization Surveillance

(<http://www.cdc.gov/flu/weekly/overview.htm#HospitalizationSurv>)

FluSurv-NET


The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

A total of 25,274 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2023, and July 13, 2024. The weekly hospitalization rate observed in Week 28 was 0.1 per 100,000 population. The peak weekly hospitalization rate observed this season was 9.0 per 100,000 population and occurred during Week 52.

Among 25,274 hospitalizations, 21,371 (84.6%) were associated with influenza A virus, 3,720 (14.7%) with influenza B virus, 52 (0.2%) with influenza A virus and influenza B virus co-infection, and 131 (0.5%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 4,238 (67.8%) were A(H1N1)pdm09 and 2,009 (32.2%) were A(H3N2).

Laboratory-Confirmed Influenza Hospitalizations
Preliminary cumulative rates as of Jul 13, 2024

FluSurv-NET :: Entire Network :: Overall Age Group :: Cumulative Rate



- All Seasons
- 2023-24
- 2022-23
- 2021-22
- 2020-21
- 2019-20
- 2018-19
- 2017-18
- 2016-17
- 2015-16
- 2014-15
- 2013-14
- 2012-13
- 2011-12
- 2010-11
- 2009-10

View National and Regional Level Graphs and Data (<https://gis.cdc.gov/grasp/fluview/FluHospRates.html>) | Download Chart Data | Download PowerPoint Presentation

**In this figure, weekly rates for all seasons prior to the 2023-2024 season reflect end-of-season rates. For the 2023-2024 season, rates for recent hospital admissions are subject to reporting delays and are shown as a dashed line for the current season. As hospitalization data are received each week, prior case counts and rates are updated accordingly.

Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#FluSurvNet>) | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity (<http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html>) or Data on Patient Characteristics (<http://gis.cdc.gov/grasp/fluview/FluHospChars.html>) | RESP-NET Interactive (<https://www.cdc.gov/surveillance/resp-net/dashboard.html>)

National Healthcare Safety Network (NHSN) Hospitalization Surveillance

Effective May 1, 2024, hospitals are no longer required to report hospital admissions, hospital capacity, or hospital occupancy data to HHS through NHSN. Voluntarily reported NHSN hospital data can found at [Weekly United States Hospitalization Metrics by Jurisdiction](https://data.cdc.gov/Public-Health-Surveillance/Weekly-United-States-Hospitalization-Metrics-by-Ju/aemt-mg7g/about_data) (https://data.cdc.gov/Public-Health-Surveillance/Weekly-United-States-Hospitalization-Metrics-by-Ju/aemt-mg7g/about_data).

Additional NHSN Hospitalization Surveillance information:

[Surveillance Methods](https://www.cdc.gov/flu/weekly/overview.htm#NHSN) (<https://www.cdc.gov/flu/weekly/overview.htm#NHSN>) | [Additional Data](https://data.cdc.gov/Public-Health-Surveillance/Weekly-United-States-Hospitalization-Metrics-by-Ju/aemt-mg7g/about_data) (https://data.cdc.gov/Public-Health-Surveillance/Weekly-United-States-Hospitalization-Metrics-by-Ju/aemt-mg7g/about_data) | [FluView Interactive](http://gis.cdc.gov/grasp/fluview/FluView12.html) (<http://gis.cdc.gov/grasp/fluview/FluView12.html>)

Mortality Surveillance

(<https://www.cdc.gov/flu/weekly/overview.htm#MortalitySurveillance>)

National Center for Health Statistics (NCHS) Mortality Surveillance


Based on NCHS mortality surveillance data available on July 18, 2024, the percentage of deaths that were due to influenza remained stable (<0.1 percentage point change) compared to the previous week. The data presented are preliminary and may change as more data are received and processed.

Season: 2023-24 Surveillance Area: National Age: All

Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System

National Summary data through the week ending July 13, 2024

2019-24 Show Number of Influenza Deaths



[View Regional and State Level Data \(https://gis.cdc.gov/grasp/fluview/Mortality.html\)](https://gis.cdc.gov/grasp/fluview/Mortality.html) | [Download Chart Data](#) | [Download PowerPoint Presentation](#)

<

Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

[Surveillance Methods \(https://www.cdc.gov/flu/weekly/overview.htm#NCHSMortality\)](https://www.cdc.gov/flu/weekly/overview.htm#NCHSMortality) | [FluView Interactive](#)

<https://gis.cdc.gov/grasp/fluview/mortality.html>


Influenza-Associated Pediatric Mortality

Two influenza-associated pediatric deaths were reported to CDC during Week 28.

One death occurred during Week 15 of the 2023-2024 season (the week ending April 13, 2024), bringing the total pediatric deaths for this season to 187. The other death occurred during Week 22 of the 2022-2023 season (the week ending June 3, 2023), which brings the total number of pediatric deaths for last season to 186. Both deaths were associated with an influenza B virus with no lineage determined.

Influenza-Associated Pediatric Deaths by Week of Death, 2020-21 season to 2023-24 season

Select up to 4 Seasons ▾ Group By Reported Virus Type
 By Week Current Week Previous Weeks All Deaths



[View FluView Interactive \(https://gis.cdc.gov/grasp/fluview/PedFluDeath.html\)](https://gis.cdc.gov/grasp/fluview/PedFluDeath.html) | [Download Chart Data](#) | [Download PowerPoint Presentation](#)

Additional pediatric mortality surveillance information for current and past seasons:

[Surveillance Methods \(https://www.cdc.gov/flu/weekly/overview.htm#PediatricMortality\)](https://www.cdc.gov/flu/weekly/overview.htm#PediatricMortality) | [FluView Interactive \(https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html\)](https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html)

Trend Indicators

- Increasing:
- Decreasing:
- Stable:

Indicators Status by System

Clinical Labs: Up or down arrows indicate a change of greater than or equal to 0.5 percentage points in the percent of specimens positive for influenza compared to the previous week.

Outpatient Respiratory Illness (ILINet): Up or down arrows indicate a change of greater than 0.1 percentage points in the percent of visits due to respiratory illness (ILI) compared to the previous week.

NHSN Hospitalizations: Up or down arrows indicate change of greater than or equal to 5% of the number of patients admitted with laboratory-confirmed influenza compared to the previous week.

NCHS Mortality: Up or down arrows indicate change of greater than 0.1 percentage points of the percent of deaths due to influenza compared to the previous week.

Reference Footnotes

¹U.S. Influenza Surveillance: Purpose and Methods (2023 Oct). Centers for Disease Control and Prevention.

<https://www.cdc.gov/flu/weekly/overview.htm#ILINet> (<https://www.cdc.gov/flu/weekly/overview.htm#ILINet>).

²Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. *MMWR Recomm Rep* 2023;72(No. RR-2):1–25.

DOI: <http://dx.doi.org/10.15585/mmwr.rr7202a1>  (<http://dx.doi.org/10.15585/mmwr.rr7202a1>)

³Influenza Antiviral Medications: Summary for Clinicians (2023 Sept). Centers for Disease Control and Prevention.

<https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm> (<https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>).

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These [FluView Interactive applications](http://www.cdc.gov/flu/weekly/fluviewinteractive.htm) (<http://www.cdc.gov/flu/weekly/fluviewinteractive.htm>) allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are [available from NIOSH](https://www.cdc.gov/niosh/topics/absences/default.html) (<https://www.cdc.gov/niosh/topics/absences/default.html>).

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information.

[Alabama](http://adph.org/influenza/) (<http://adph.org/influenza/>)

[Alaska](http://dhss.alaska.gov/dph/Epi/id/Pages/influenza/fluinf)

(<http://dhss.alaska.gov/dph/Epi/id/Pages/influenza/fluinf>)

[Colorado](https://www.mass.gov/info-details/influenza-reporting) (<https://www.mass.gov/info-details/influenza-reporting>)

[Connecticut](https://portal.ct.gov/DPH/Epidemiology-Emerging-Infections/Influenza-Surveillance-and-Statist) (<https://portal.ct.gov/DPH/Epidemiology-Emerging-Infections/Influenza-Surveillance-and-Statist>)

[Georgia](https://dph.georgia.gov/flu-activity-georgia) (<https://dph.georgia.gov/flu-activity-georgia>)

[Hawaii](#)

(<http://health.hawaii.gov/docd/resources/reports/influenza-reports/>)

Iowa (<https://idph.iowa.gov/influenza/reports>)

Kansas (<http://www.kdheks.gov/flu/surveillance.htm>)

Maryland (<https://phpa.health.maryland.gov/influenza/fluwatch/>)

Massachusetts (<https://www.mass.gov/info-details/influenza-reporting>)

Missouri
(<http://health.mo.gov/living/healthcondiseases/communicable/influenza/reports.php>)

Montana
(<https://dphhs.mt.gov/publichealth/cdepi/diseases/Pan-Respiratory/index>)

New Jersey (<http://www.nj.gov/health/cd/topics/flu.shtml>)

New Mexico (<https://nmhealth.org/about/erd/ideb/isp>)

Ohio (<http://www.flu.ohio.gov>)

Oklahoma (<https://oklahoma.gov/health/health-education/acute-disease-service/disease-information/influenza-home-page.html>)

South Carolina
(<http://www.scdhec.gov/Health/DiseasesandConditions/InfectiousDiseases/Flu/FluData/>)

South Dakota (<https://doh.sd.gov/health-data-reports/data-dashboards/influenza-dashboard/>)

Vermont (<http://www.healthvermont.gov/immunizations-infectious-disease/influenza/flu-activity-and-surveillance>)

Virginia
(<http://www.vdh.virginia.gov/epidemiology/influenza-flu-virginia/influenza-surveillance/>)

Wyoming (<https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/influenza/>)

New York City
(<http://www1.nyc.gov/site/doh/providers/health-topics/alerts.page>)

World Health Organization:

Additional influenza surveillance information from participating WHO member nations is available through FluNet [🔗](https://www.who.int/tools/flunet) (<https://www.who.int/tools/flunet>) and the Global Epidemiology Reports. [🔗](https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs) (<https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs>)


WHO Collaborating Centers for Influenza:

Australia [🔗](http://www.influenzacentre.org/Surveillance_Samples_Received.html) (http://www.influenzacentre.org/Surveillance_Samples_Received.html), China [🔗](http://www.chinaivdc.cn/cnic/) (<http://www.chinaivdc.cn/cnic/>), Japan [🔗](http://idsc.nih.go.jp/index.html) (<http://idsc.nih.go.jp/index.html>), the United Kingdom [🔗](https://www.crick.ac.uk/research/worldwide-influenza-centre) (<https://www.crick.ac.uk/research/worldwide-influenza-centre>), and the United States (<http://www.cdc.gov/flu/>) (CDC in Atlanta, Georgia)

Europe:

The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control [🔗](http://www.flunewseurope.org/) (<http://www.flunewseurope.org/>).

Public Health Agency of Canada:

The most up-to-date influenza information from Canada is available in [Canada's weekly FluWatch report](http://www.phac-aspc.gc.ca/fluwatch/)  (<http://www.phac-aspc.gc.ca/fluwatch/>).

Public Health England:

The most up-to-date influenza information from the United Kingdom is available from [Public Health England](http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/)  (<http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/>).

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the [surveillance methods](http://www.cdc.gov/flu/weekly/overview.htm) (<http://www.cdc.gov/flu/weekly/overview.htm>) page.

Last Reviewed: July 19, 2024, 11:00 AM

Source: Centers for Disease Control and Prevention (<https://www.cdc.gov/>), National Center for Immunization and Respiratory Diseases (NCIRD) (<https://www.cdc.gov/ncird/index.html>)

How helpful was this page?



Not helpful

Very helpful